Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. (ORMP) generates news at the intersection of clinical-stage drug development, oral delivery technology, and strategic healthcare investments. The company describes itself as a platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, centered on its Protein Oral Delivery (POD™) technology and a refined oral insulin program.
News about Oramed often covers clinical and strategic milestones for its oral insulin and POD™ platform, including updates on trial design, analysis of Phase 2 and Phase 3 data, and plans for U.S.-based clinical studies. Company letters to shareholders and press releases provide context on how Oramed is advancing its oral insulin program independently and how it evaluates high-responder subgroups in its clinical data.
Another major source of headlines is Oramed’s investment and partnership activity across the biomedical and medical technology landscape. Releases have detailed structured financings and royalty arrangements with Scilex Holding Company, a substantial equity investment and strategic collaboration with Alpha Tau Medical Ltd., and positions in companies such as BioXcel Therapeutics Inc. and Pelthos Therapeutics Inc. These updates often discuss repayments, warrant structures, royalty interests, and unrealized gains.
Recent news also highlights transformative corporate transactions, such as the announced transfer of Oramed’s POD™ technology to Lifeward Ltd. in exchange for a significant beneficial ownership interest and participation in a revenue-generating medical robotics business. Additional items include stock repurchase programs, cash dividend declarations, and the adoption of a Rights Agreement involving common stock purchase rights.
Investors and followers of ORMP news can use this page to review Oramed’s press releases, shareholder letters, and transaction announcements in one place, tracking developments in its oral drug delivery platform, strategic investments, and corporate actions over time.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. This virtual event will start at 7:00 a.m. Eastern time and can be viewed online. Oramed is focused on oral drug delivery, particularly its lead candidate ORMD-0801, which aims to be the first commercial oral insulin capsule for diabetes treatment, currently in pivotal Phase 3 studies.
Oramed Pharmaceuticals has announced the enrollment of over 25% of its target of 450 patients in the Phase 3 ORA-D-013-2 trial for its oral insulin capsule, ORMD-0801, aimed at treating type 2 diabetes. This trial is one of two ongoing Phase 3 trials approved by the FDA. The study will assess the efficacy of ORMD-0801 in improving glycemic control compared to placebo over 26 weeks, with a secondary aim to maintain control over 52 weeks. Results from the concurrent ORA-D-013-1 trial, which enrolled nearly 65% of its 675 patients, are expected in 2022.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced the publication of a study in Diabetes, Obesity, and Metabolism evaluating the efficacy and safety of its oral insulin candidate ORMD-0801 for type 2 diabetes. The trial met its primary endpoint, demonstrating that ORMD-0801 effectively managed nighttime and 24-hour glycemia levels without increasing hypoglycemia risks compared to placebo. This study supports Oramed's efforts to develop the first commercial oral insulin capsule, as it undergoes two pivotal Phase 3 trials.
On August 9, 2021, Oramed Pharmaceuticals (Nasdaq: ORMP) announced that Chief Commercial Officer Michael Rabinowitz will present a company overview at the Canaccord Genuity's 41st Annual Growth Conference, taking place virtually from August 10-12, 2021. Rabinowitz's presentation is scheduled for August 12 at 11:30 a.m. Eastern and can be viewed online. Oramed is a clinical-stage pharmaceutical company specializing in oral drug delivery systems, focusing on its lead candidate ORMD-0801, aimed at transforming diabetes treatment.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that its majority-owned company Oravax Medical will present its oral COVID-19 vaccine during a Keynote Talk at the Arena International Vaccines Virtual Conference on August 5, 2021. The presentation, led by Oramed CEO Nadav Kidron, will cover the development of the world's first triple antigen oral SARS-CoV-2 vaccine that targets three virus surface proteins. This innovative approach aims to enhance effectiveness against current and future COVID-19 variants.
Oramed Pharmaceuticals Inc. has appointed Michael Rabinowitz as the first Chief Commercial Officer to lead its commercial strategy starting August 1, 2021. This move comes as the company advances its Phase III trials for ORMD-0801, an innovative oral insulin candidate. Rabinowitz brings over 20 years of experience from Merck, where he successfully launched products globally. His appointment is seen as a strategic step towards enhancing Oramed's commercialization efforts.
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) announced significant updates regarding its majority-owned company, Oravax Medical Inc., which is advancing an oral COVID-19 vaccine utilizing proprietary protein oral delivery technology. Preclinical trials are underway against COVID-19 variants, with plans to initiate clinical trials in Israel soon. The vaccine targets multiple viral proteins to enhance its efficacy against current and future variants. Additionally, Oravax has out-licensed the rights for an injectable version of the vaccine in India to Premas Biotech, aiming to address urgent vaccination needs.
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) will join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index, effective June 28, 2021. This inclusion follows the annual reconstitution and provides significant visibility among institutional investors, as approximately $10.6 trillion is benchmarked against Russell's indexes. Oramed specializes in oral drug delivery systems, aiming to innovate diabetes treatment with its lead candidate, ORMD-0801, targeting the development of the first commercial oral insulin capsule.
Oramed Pharmaceuticals, focused on oral drug delivery systems, has announced it has enrolled over 50% of the 675 patients for its Phase 3 ORA-D-013-1 study of oral insulin capsule ORMD-0801 for type 2 diabetes. The study aims to compare the efficacy of ORMD-0801 to placebo over 6 to 12 months, assessing glycemic control via A1c levels. Concurrently, ORA-D-013-2 is enrolling 450 patients. Topline results are expected in 2022, positioning ORMD-0801 to potentially be the first commercial oral insulin for diabetes treatment.
Oramed Pharmaceuticals has achieved significant milestones in developing its oral drug delivery system. The company is advancing its lead programs: ORMD-0801, aimed at type 2 diabetes, with two Phase 3 studies currently underway, and an oral COVID-19 vaccine via Oravax Medical, set for clinical trials in H2 2021. Oramed boasts a strong financial position with over $75 million in cash and no debt, allowing for further progress in its initiatives. Shareholders may benefit from potential dividends from Oravax shares, enhancing overall company value.
FAQ
What is the current stock price of Oramed Pharmaceuticals (ORMP)?
What is the market cap of Oramed Pharmaceuticals (ORMP)?
